Last reviewed · How we verify
Pueraria lobata
Pueraria lobata (kudzu root) contains isoflavones and other phytochemicals that modulate estrogen signaling and reduce inflammation.
Pueraria lobata (kudzu root) contains isoflavones and other phytochemicals that modulate estrogen signaling and reduce inflammation. Used for Menopausal symptoms (hot flashes, night sweats), Alcohol use disorder (craving reduction), Cardiovascular support and lipid management.
At a glance
| Generic name | Pueraria lobata |
|---|---|
| Sponsor | Jiangxi University of Traditional Chinese Medicine |
| Drug class | Herbal extract / Phytoestrogen |
| Modality | Small molecule |
| Therapeutic area | Women's Health, Cardiovascular, Addiction Medicine |
| Phase | FDA-approved |
Mechanism of action
The root extract is rich in daidzein, genistein, and puerarin, which act as phytoestrogens and antioxidants. These compounds are believed to improve menopausal symptoms, support cardiovascular health, and reduce alcohol craving through multiple pathways including estrogen receptor modulation and inhibition of inflammatory cytokines.
Approved indications
- Menopausal symptoms (hot flashes, night sweats)
- Alcohol use disorder (craving reduction)
- Cardiovascular support and lipid management
Common side effects
- Gastrointestinal upset
- Headache
- Rash or allergic reaction
Key clinical trials
- Safety Evaluation of Pueraria Lobata Radix in Specific Consumption Scenarios for Type 2 Diabetes
- Efficacy and Safety of Pueraria Lobata Radix As an Adjuvant Treatment for Type 2 Diabetes Mellitus (NA)
- Pueraria Lobata and Pueraria Thomsonii for Mild Dyslipidemia (NA)
- RCT of a Polyherbal Dietary Supplement for Prediabetes (NA)
- Evaluate the Efficacy of Herbal Medicine (Shaoyao Gancao Decoction Jiawei) in Sleep-related Leg Cramps (NA)
- Efficacy and Safety of Modified Gegen Qinlian Decoction for Diarrhea-predominant Irritable Boewl Syndrome (EARLY_PHASE1)
- Efficacy and Safety of Modified Gegen Qinlian Decoction for Ulcerative Colitis With Damp-heat Syndrome (EARLY_PHASE1)
- Clinical Trial to Assess the Efficacy and to Evaluate Safety of HT047 in Patients With Acute Ischemic Stroke (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pueraria lobata CI brief — competitive landscape report
- Pueraria lobata updates RSS · CI watch RSS
- Jiangxi University of Traditional Chinese Medicine portfolio CI